doi: 10.1016/j.jsbmb.2024.106632 153 AthariSS
Prostaglandins, arachidonic acid, and inflammation
Mark Cuban (22:28): Yeah, it's all vertically integrated
Patient-Friendly Timeline Retatrutide, CagriSema, and orforglipron are currently in Phase 3 testing
Tissue regeneration involves activating cells responsible for repairing damaged intestinal walls, sealing ulcers, and restoring normal gut function, allowing BPC-157 to work on rebuilding the gut barrier, protect against leaky gut and lesions caused by toxins or NSAIDs, and maintain overall gastrointestinal resilience
however, topical drug delivery offers distinct advantages by enabling localized symptom modulation, minimizing systemic side effects, and enhancing patient compliance